Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma ; volume:85 ; number:5 ; day:28 ; month:3 ; year:2020 ; pages:831-842 ; date:5.2020
Cancer chemotherapy and pharmacology ; 85, Heft 5 (28.3.2020), 831-842, 5.2020
- Creator
-
Shemesh, Colby S.
Agarwal, Priya
Lu, Tong
Lee, Calvin
Dere, Randall C.
Li, Xiaobin
Li, Chunze
Jin, Jin Y.
Girish, Sandhya
Miles, Dale
Lu, Dan
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00280-020-04054-8
- URN
-
urn:nbn:de:101:1-2020070901192906865644
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:55 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Shemesh, Colby S.
- Agarwal, Priya
- Lu, Tong
- Lee, Calvin
- Dere, Randall C.
- Li, Xiaobin
- Li, Chunze
- Jin, Jin Y.
- Girish, Sandhya
- Miles, Dale
- Lu, Dan
- SpringerLink (Online service)
Other Objects (12)
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
Fa. Ch.P. Heinrich - Paris
Wappen + CHP? = Cantus, S.21/24
Wappen + CHP? = Cantus, S.21/24
Wappen + CHP? = Cantus, S.21+24
CHP İstanbul İl kongresi 1968
Polatuzumab Vedotin: First Global Approval
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
Fa. Ch.P. Heinrich - Paris
Wappen + CHP? = Cantus, S.21/24
Wappen + CHP? = Cantus, S.21/24
Wappen + CHP? = Cantus, S.21+24
CHP İstanbul İl kongresi 1968
Polatuzumab Vedotin: First Global Approval
Population pharmacokinetics of inotuzumab ozogamicin in relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma
Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma
Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
Fa. Ch.P. Heinrich - Paris
Wappen + CHP? = Cantus, S.21/24
Wappen + CHP? = Cantus, S.21/24
Wappen + CHP? = Cantus, S.21+24
CHP İstanbul İl kongresi 1968
Polatuzumab Vedotin: First Global Approval